Tag Archives: cost
May 2010 Br J Cardiol 2010;17:s14-s15
Costs and benefits of ARBs in practice
David Taylor, Mark Davis
This brief paper considers how such cost pressures may affect the use of angiotensin receptor blockers (ARBs) in the NHS, given that although losartan is the first drug in this class to become generic in March 2010, others will quickly follow suit. Valsartan loses patent protection in 2011, with candesartan and irbesartan following in 2012. Indications for ARB use Recent data indicate that candesartan is presently the most widely used ARB in England, accounting for almost a third of all ARB prescriptions. This is in part because it has been competitively priced compared with other ARBs. In average prescription cost terms, candesartan has in r
July 2004 Br J Cardiol 2004;11:307-9
Is provision and funding of cardiac rehabilitation services sufficient for the achievement of the National Service Framework goals?
Ingolf Griebsch, Jackie Brown, Andrew D Beswick, Karen Rees, Robert West, Fiona Taylor, Rod Taylor, Jackie Victory, Margaret Burke, Sally Turner, Hugh Bethell, Shah Ebrahim
No content available
For healthcare professionals only
